SPYRE THERAPEUTICS, INC.
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2021 | $26.0M | $109.9M | $15.1M |
| FY2022 | $20.8M | $71.1M | $34.9M |
| FY2023 | $73.3M | $341.9M | $188.9M |
| FY2024 | $90.7M | $608.5M | $89.4M |
| FY2025 | $62.5M | $777.8M | $85.7M |
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2021 | $26.0M | $109.9M | $15.1M |
| FY2022 | $20.8M | $71.1M | $34.9M |
| FY2023 | $73.3M | $341.9M | $188.9M |
| FY2024 | $90.7M | $608.5M | $89.4M |
| FY2025 | $62.5M | $777.8M | $85.7M |